AP2007004137A0 - Nucleic acid constructs - Google Patents

Nucleic acid constructs

Info

Publication number
AP2007004137A0
AP2007004137A0 AP2007004137A AP2007004137A AP2007004137A0 AP 2007004137 A0 AP2007004137 A0 AP 2007004137A0 AP 2007004137 A AP2007004137 A AP 2007004137A AP 2007004137 A AP2007004137 A AP 2007004137A AP 2007004137 A0 AP2007004137 A0 AP 2007004137A0
Authority
AP
ARIPO
Prior art keywords
nucleic acid
acid constructs
constructs
nucleic
acid
Prior art date
Application number
AP2007004137A
Other languages
English (en)
Inventor
James Fuller
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of AP2007004137A0 publication Critical patent/AP2007004137A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AP2007004137A 2005-02-01 2006-02-01 Nucleic acid constructs AP2007004137A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64838205P 2005-02-01 2005-02-01
US67249705P 2005-04-19 2005-04-19
GBGB0507997.5A GB0507997D0 (en) 2005-02-01 2005-04-20 Nucleic acid constructs
PCT/GB2006/000344 WO2006082398A2 (fr) 2005-02-01 2006-02-01 Constructions d'acide nucleique

Publications (1)

Publication Number Publication Date
AP2007004137A0 true AP2007004137A0 (en) 2007-08-31

Family

ID=36178086

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004137A AP2007004137A0 (en) 2005-02-01 2006-02-01 Nucleic acid constructs

Country Status (20)

Country Link
US (1) US20100221349A1 (fr)
EP (1) EP1850869A2 (fr)
JP (1) JP2008528020A (fr)
KR (1) KR20070100403A (fr)
CN (1) CN101155597A (fr)
AP (1) AP2007004137A0 (fr)
AU (1) AU2006210716A1 (fr)
BR (1) BRPI0607119A2 (fr)
CA (1) CA2596731A1 (fr)
EA (1) EA011557B1 (fr)
GB (1) GB0507997D0 (fr)
IL (1) IL184653A0 (fr)
MA (1) MA29274B1 (fr)
MX (1) MX2007009164A (fr)
NI (1) NI200700191A (fr)
NO (1) NO20074421L (fr)
SG (1) SG158902A1 (fr)
TN (1) TNSN07295A1 (fr)
WO (1) WO2006082398A2 (fr)
ZA (1) ZA200707522B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1685251E (pt) * 2003-10-10 2014-04-15 Powderject Vaccines Inc Construções de ácido nucleico
WO2007067680A2 (fr) * 2005-12-05 2007-06-14 Guava Technologies Caractérisation d'analyse à base particulaire
EP1925318A1 (fr) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Vaccin à base de virus modifié de vaccin Ankara (MVA) recombinant contre la grippe aviaire
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2715078C (fr) * 2007-09-26 2019-07-23 Intrexon Corporation Regions non traduites 5' (5'utr) synthetiques, vecteurs d'expression, et procedes pour augmenter l'expression transgenique
CA2705461A1 (fr) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccins contre plusiseurs sous-types de virus de l'influenza
WO2009092038A1 (fr) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccination a base d'adn de la grippe et methodes d'utilisation associees
EP2358386B1 (fr) * 2008-11-28 2016-11-02 Statens Serum Institut Vaccin optimisé contre la grippe
ES2759015T3 (es) 2010-02-10 2020-05-07 Mayo Found Medical Education & Res Métodos y materiales para tratar el cáncer
EP2825693B1 (fr) * 2012-03-15 2018-05-30 Mayo Foundation For Medical Education And Research Méthodes et matériaux de traitement du cancer
CN103740715B (zh) * 2013-12-25 2016-03-23 北京大北农科技集团股份有限公司 嵌合启动子及其用途
CN103901209B (zh) * 2014-02-18 2016-05-25 王明丽 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
WO2015143221A1 (fr) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Méthodes et matériels pour le traitement du cancer
US10188713B2 (en) 2014-03-19 2019-01-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN105120042B (zh) * 2015-09-09 2019-02-12 小米科技有限责任公司 移动终端
WO2017059902A1 (fr) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh Séquences utr 3' permettant la stabilisation d'arn
WO2018013704A1 (fr) 2016-07-12 2018-01-18 Duke University Polynucléotides, virus, vaccins anti-grippaux modifiés et leurs procédés de préparation et d'utilisation
WO2019121513A1 (fr) 2017-12-18 2019-06-27 Intervet International B.V. Vaccin contre le virus de la grippe porcine de type a
US12337025B2 (en) 2018-05-07 2025-06-24 The Administrators Of The Tulane Educational Fund Mutated e. coli enterotoxins as anti-inflammatory agents
WO2020163768A1 (fr) 2019-02-07 2020-08-13 Duke University Virus de la grippe segmentés en 9 et 10 stabilisés en tant que plateforme de vaccin et procédés de fabrication et d'utilisation de ceux-ci
US20240084267A1 (en) * 2021-01-12 2024-03-14 Duke University Compositions and methods for the genetic manipulation of the influenza virus
WO2024097894A1 (fr) * 2022-11-04 2024-05-10 RNAimmune, Inc. Compositions et procédés de vaccins à base d'acide ribonucléique codant nye-so-1
CN120611983B (zh) * 2025-08-11 2025-10-03 安徽省农业科学院水稻研究所 基于多指标融合的生物技术产品风险动态识别方法及系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US5100792A (en) * 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
DK0690732T3 (da) * 1994-01-21 2003-05-19 Powderject Vaccines Inc Gasdrevet genindførselsinstrument
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
ES2261489T3 (es) * 2000-10-13 2006-11-16 Chiron Corporation Fragmentos de intron a de citomegalovirus.
DK1379273T3 (da) * 2000-11-27 2009-11-09 Powderject Vaccines Inc Nukleinsyreadjuvanser
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
PT1685251E (pt) * 2003-10-10 2014-04-15 Powderject Vaccines Inc Construções de ácido nucleico
EA012066B1 (ru) * 2003-10-10 2009-08-28 Паудерджект Вэксинс, Инк. Способ, вызывающий т-клеточный ответ

Also Published As

Publication number Publication date
WO2006082398A2 (fr) 2006-08-10
NI200700191A (es) 2008-02-05
MX2007009164A (es) 2008-03-13
EA200701643A1 (ru) 2008-02-28
EA011557B1 (ru) 2009-04-28
CN101155597A (zh) 2008-04-02
ZA200707522B (en) 2008-08-27
WO2006082398A3 (fr) 2006-10-19
IL184653A0 (en) 2007-12-03
AU2006210716A1 (en) 2006-08-10
JP2008528020A (ja) 2008-07-31
KR20070100403A (ko) 2007-10-10
TNSN07295A1 (en) 2008-12-31
GB0507997D0 (en) 2005-05-25
CA2596731A1 (fr) 2006-08-10
US20100221349A1 (en) 2010-09-02
NO20074421L (no) 2007-10-31
EP1850869A2 (fr) 2007-11-07
MA29274B1 (fr) 2008-02-01
SG158902A1 (en) 2010-02-26
BRPI0607119A2 (pt) 2009-08-11

Similar Documents

Publication Publication Date Title
IL184653A0 (en) Nucleic acid constructs
PL1807520T3 (pl) Konstrukty do RNA
IL174848A0 (en) Nucleic acid constructs
EP2123752A4 (fr) Nouvel acide nucléique
EP2077326A4 (fr) Nouvel acide nucléique
IL196676A0 (en) Regulatory nucleic acid elements
GB0706243D0 (en) Modified nucleic acids
DE602006010048D1 (en) Biosensor
GB0507679D0 (en) Micro RNA
GB0603160D0 (en) Nucleic acid
SG10201500691UA (en) Nucleic acid concatenation
GB0406863D0 (en) Nucleic acid sequencing
ZA200708154B (en) Nucleic acid detection
GB0604615D0 (en) RNA labelling
GB0522578D0 (en) Ribozymal nucleic acid
SG122904A1 (en) Nucleic acid preparation
GB0423659D0 (en) RNA constructs
GB0406865D0 (en) Nucleic acid sequencing
GB0516574D0 (en) Nucleic acid molecule
GB0406864D0 (en) Nucleic acid sequencing
GB0521187D0 (en) Nucleic acid analysis
GB0423873D0 (en) Nucleic acid analysis
GB0523544D0 (en) A nucleic acid molecule
GB0420088D0 (en) Nucleic acid molecule
GB0414034D0 (en) Nucleic acid preparation